Seminars in Oncology
Volume 35, Supplement 3 , Pages S6-S12, June 2008

Exploring the Mechanisms of Action of the Novel Microtubule Inhibitor Vinflunine

  • Mary Ann Jordan

      Affiliations

    • University of California-Santa Barbara, Santa Barbara, CA.
    • Corresponding Author InformationAddress correspondence to Mary Ann Jordan, PhD, Department of Molecular, Cellular & Developmental Biology, Mail Code 9610, University of California-Santa Barbara, Santa Barbara, CA 93106
  • ,
  • Susan Band Horwitz

      Affiliations

    • Albert Einstein College of Medicine, Bronx, NY.
  • ,
  • Sharon Lobert

      Affiliations

    • University of Mississippi Medical Center, Jackson, MS.
  • ,
  • John J. Correia

      Affiliations

    • University of Mississippi Medical Center, Jackson, MS.

Microtubules have been identified as a suitable target for anticancer therapy, primarily based on their biological importance in coordinating chromosomal segregation at mitosis. Two main classes of microtubule-targeted agents, the taxanes and vinca alkaloids, suppress the dynamic behavior of spindle microtubules, inducing mitotic arrest and subsequent apoptotic cell death. Clinical activity of taxanes and first-generation vinca alkaloids in the treatment of solid tumors and hematologic malignancies, respectively, has prompted further research for novel analogs with improved clinical efficacy and safety. Such efforts have led to the development of vinflunine, a bifluorinated vinca alkaloid endowed with unique antitumor properties. Highlighted in this review are the key features of vinflunine that lead to effective suppression of microtubule dynamics and induction of cell death in cancer cells.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Dr Jordan has received research support and consulting fees from Bristol-Myers Squibb. Dr Horwitz does not have any financial conflict to report. Dr Lobert has received research support from Pierre Fabre Oncologie and consulting fees from Pierre Fabre Oncologie and Bristol-Myers Squibb. Dr Correia has received research support from Pierre Fabre Oncologie and consulting fees from Pierre Fabre Oncologie, Bristol-Myers Squibb, and Eisai.

PII: S0093-7754(08)00018-3

doi:10.1053/j.seminoncol.2008.01.009

Seminars in Oncology
Volume 35, Supplement 3 , Pages S6-S12, June 2008